百奥泰：托珠单抗皮下制剂已完成临床试验，目前正积极推进申报前各项准备工作

Group 1 - The core point of the article is that the company Baiotai (688177.SH) has completed clinical trials for the subcutaneous formulation of tocilizumab and is actively preparing for the submission of relevant applications [1] Group 2 - Investors inquired about the progress of the subcutaneous tocilizumab and the timeline for domestic application and overseas authorization [1]